PainReform Ltd.
2.82
0.08 (2.92%)
At close: Jan 15, 2025, 9:52 AM

Company Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel.

It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.

The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair.

PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

PainReform Ltd.
PainReform Ltd. logo
Country IL
IPO Date Sep 1, 2020
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 7
CEO Dr. Ehud Geller Ph.D.

Contact Details

Address:
65 Yigal Alon Street
Tel Aviv,
IL
Website https://www.painreform.com

Stock Details

Ticker Symbol PRFX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001801834
CUSIP Number M77798102
ISIN Number IL0011651580
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Ehud Geller Ph.D. Interim Chief Executive Officer & Executive Chairman
Dr. Sigal Aviel Chief Operating Officer
Eyal Broder Interim Chief Financial Officer
Prof. Eli Hazum Ph.D. Chief Technology Officer & Director
Dr. Stephen A. Cooper D.M.D Ph.D. Executive Vice President of Development
Rita Keynan Vice President of Pharmaceutical Operations

Latest SEC Filings

Date Type Title
Jan 02, 2025 424B5 Filing
Jan 02, 2025 6-K Filing
Dec 27, 2024 6-K Filing
Dec 12, 2024 424B3 Filing
Dec 06, 2024 F-3 Filing
Dec 04, 2024 6-K Filing
Nov 20, 2024 6-K Filing
Nov 18, 2024 6-K Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...